메뉴 건너뛰기




Volumn 150, Issue 9, 2014, Pages 945-951

Global burden of skin disease as reflected in Cochrane Database of Systematic Reviews

(15)  Karimkhani, Chante a   Boyers, Lindsay N b   Prescott, Laura c   Welch, Vivian d   Delamere, Finola M e   Nasser, Mona f   Zaveri, Amrapali g   Hay, Roderick J h   Vos, Theo i   Murray, Christopher J L i   Margolis, David J j   Hilton, John k   MacLehose, Harriet k   Williams, Hywel C c   Dellavalle, Robert P l,m  


Author keywords

[No Author keywords available]

Indexed keywords

ACNE VULGARIS; ACTINIC KERATOSIS; ALOPECIA AREATA; ARTICLE; BACTERIAL SKIN DISEASE; CELLULITIS; CHLOASMA; CLINICAL PROTOCOL; COMPARATIVE STUDY; DATA ANALYSIS; DECUBITUS; DERMATITIS; DISABILITY; DISABILITY ADJUSTED LIFE YEAR; DISEASE BURDEN; GENERAL PATHOLOGICAL PARAMETERS; HUMAN; HYPERTRICHOSIS; INGROWN NAIL; KELOID; LEPROSY; LICHEN PLANUS; LICHEN SCLEROSUS ET ATROPHICUS; LOCALIZED SCLERODERMA; LUPUS ERYTHEMATOSUS; MALE TYPE ALOPECIA; MELANOMA; MYCOSIS; NON MELANOMA SKIN CANCER; PEDICULOSIS; PEMPHIGOID; PEMPHIGUS; PHOTODAMAGE; PHOTODERMATOSIS; PITYRIASIS ROSEA; PRURITUS; PSORIASIS; RADIATION DERMATITIS; ROSACEA; SCABIES; SKIN DEFECT; SKIN DISEASE; SUPPURATIVE HIDRADENITIS; SWEAT GLAND DISEASE; SYSTEMATIC REVIEW (TOPIC); TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VIRAL SKIN DISEASE; VITILIGO; COST OF ILLNESS; FACTUAL DATABASE; LITERATURE; QUALITY ADJUSTED LIFE YEAR; SKIN DISEASES;

EID: 84908246482     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.709     Document Type: Article
Times cited : (80)

References (35)
  • 3
    • 84875704768 scopus 로고    scopus 로고
    • Prioritization of systematic reviews leads prioritization of research gaps and needs
    • Nasser M,Welch V. Prioritization of systematic reviews leads prioritization of research gaps and needs. J Clin Epidemiol. 2013;66(5):522-523.
    • (2013) J Clin Epidemiol. , vol.66 , Issue.5 , pp. 522-523
    • Nasser, M.1    Welch, V.2
  • 4
    • 0344665574 scopus 로고    scopus 로고
    • Measuring health in a vacuum: Examining the disability weight of the DALY
    • Reidpath DD, Allotey PA, Kouame A, Cummins RA. Measuring health in a vacuum: examining the disability weight of the DALY. Health Policy Plan. 2003;18(4):351-356.
    • (2003) Health Policy Plan. , vol.18 , Issue.4 , pp. 351-356
    • Reidpath, D.D.1    Allotey, P.A.2    Kouame, A.3    Cummins, R.A.4
  • 5
    • 79952087469 scopus 로고    scopus 로고
    • NIH disease funding levels and burden of disease
    • Gillum LA, Gouveia C, Dorsey ER, et al. NIH disease funding levels and burden of disease. PLoS One. 2011;6(2):e16837.
    • (2011) PLoS One. , vol.6 , Issue.2
    • Gillum, L.A.1    Gouveia, C.2    Dorsey, E.R.3    et al.4
  • 6
    • 84871051576 scopus 로고    scopus 로고
    • Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010
    • Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-2196.
    • (2012) Lancet , vol.380 , Issue.9859 , pp. 2163-2196
    • Vos, T.1    Flaxman, A.D.2    Naghavi, M.3    et al.4
  • 7
    • 84871047327 scopus 로고    scopus 로고
    • GBD 2010: Design, definitions, and metrics
    • Murray CJ, EzzatiM, Flaxman AD, et al. GBD 2010: design, definitions, and metrics. Lancet. 2012;380(9859):2063-2066.
    • (2012) Lancet , vol.380 , Issue.9859 , pp. 2063-2066
    • Murray, C.J.1    Ezzati, M.2    Flaxman, A.D.3    et al.4
  • 8
    • 84900812974 scopus 로고    scopus 로고
    • The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions
    • Hay RJ, Johns NE,Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2013. doi:10.1038/jid.2013.446.
    • (2013) J Invest Dermatol.
    • Hay, R.J.1    Johns, N.E.2    Williams, H.C.3    et al.4
  • 9
    • 77954750707 scopus 로고    scopus 로고
    • Clinical trials should begin and end with systematic reviews of relevant evidence: 12 years and waiting
    • ClarkeM, Hopewell S, Chalmers I. Clinical trials should begin and end with systematic reviews of relevant evidence: 12 years and waiting. Lancet. 2010;376(9734):20-21.
    • (2010) Lancet , vol.376 , Issue.9734 , pp. 20-21
    • Clarke, M.1    Hopewell, S.2    Chalmers, I.3
  • 10
    • 84908256651 scopus 로고    scopus 로고
    • Accessed November 21, 2013
    • The Cochrane Collaboration. About the Cochrane Library. http://www.thecochranelibrary .com/view/0/AboutTheCochraneLibrary .html#CDSR. Accessed November 21, 2013.
    • About the Cochrane Library
  • 11
    • 0032527547 scopus 로고    scopus 로고
    • Methodology and reports of systematic reviews and meta-analyses: A comparison of Cochrane reviews with articles published in paper-based journals
    • Jadad AR, Cook DJ, Jones A, et al.Methodology and reports of systematic reviews and meta-analyses: a comparison of Cochrane reviews with articles published in paper-based journals. JAMA. 1998;280 (3):278-280.
    • (1998) JAMA , vol.280 , Issue.3 , pp. 278-280
    • Jadad, A.R.1    Cook, D.J.2    Jones, A.3    et al.4
  • 12
    • 33947684405 scopus 로고    scopus 로고
    • Epidemiology and reporting characteristics of systematic reviews
    • Moher D, Tetzlaff J, Tricco AC, Sampson M, Altman DG. Epidemiology and reporting characteristics of systematic reviews. PLoS Med. 2007;4(3):e78.
    • (2007) PLoS Med. , vol.4 , Issue.3 , pp. e78
    • Moher, D.1    Tetzlaff, J.2    Tricco, A.C.3    Sampson, M.4    Altman, D.G.5
  • 13
    • 33750921286 scopus 로고    scopus 로고
    • Cochrane Skin Group systematic reviews are moremethodologically rigorous than other systematic reviews in dermatology
    • Collier A, Heilig L, Schilling L,Williams H, Dellavalle RP. Cochrane Skin Group systematic reviews are moremethodologically rigorous than other systematic reviews in dermatology. Br J Dermatol. 2006;155(6):1230-1235.
    • (2006) Br J Dermatol. , vol.155 , Issue.6 , pp. 1230-1235
    • Collier, A.1    Heilig, L.2    Schilling, L.3    Williams, H.4    Dellavalle, R.P.5
  • 14
    • 84908255383 scopus 로고    scopus 로고
    • Accessed December 5, 2013
    • The Cochrane Collaboration. About Cochrane systematic reviews and protocols. http://www.thecochranelibrary.com/view/0/AboutCochraneSystematicReviews.html. Accessed December 5, 2013.
    • About Cochrane Systematic Reviews and Protocols
  • 15
    • 84908244028 scopus 로고    scopus 로고
    • Accessed November 1, 2013
    • The Cochrane Collaboration. Search the Cochrane Library. http://www.thecochranelibrary .com/view/0/index.html. Accessed November 1, 2013.
    • Search the Cochrane Library
  • 16
    • 84871047327 scopus 로고    scopus 로고
    • GBD 2010: Design, definitions, and metrics
    • Murray CJ, EzzatiM, Flaxman AD, et al. GBD 2010: design, definitions, and metrics. Lancet. 2012;380(9859):2063-2066.
    • (2012) Lancet , vol.380 , Issue.9859 , pp. 2063-2066
    • Murray, C.J.1    Ezzati, M.2    Flaxman, A.D.3    et al.4
  • 19
    • 60549094452 scopus 로고    scopus 로고
    • An update on acute and chronic urticaria for the primary care provider
    • Najib U, Sheikh J. An update on acute and chronic urticaria for the primary care provider. Postgrad Med. 2009;121(1):141-151.
    • (2009) Postgrad Med. , vol.121 , Issue.1 , pp. 141-151
    • Najib, U.1    Sheikh, J.2
  • 20
    • 0034746255 scopus 로고    scopus 로고
    • Understanding pruritus in systemic disease
    • Krajnik M, Zylicz Z. Understanding pruritus in systemic disease. J Pain SymptomManage. 2001;21 (2):151-168.
    • (2001) J Pain SymptomManage. , vol.21 , Issue.2 , pp. 151-168
    • Krajnik, M.1    Zylicz, Z.2
  • 21
    • 84858627615 scopus 로고    scopus 로고
    • Scabies in the developing world - Its prevalence, complications, and management
    • Hay RJ, Steer AC, Engelman D,Walton S. Scabies in the developing world - its prevalence, complications, and management. Clin Microbiol Infect. 2012;18(4):313-323.
    • (2012) Clin Microbiol Infect. , vol.18 , Issue.4 , pp. 313-323
    • Hay, R.J.1    Steer, A.C.2    Engelman, D.3    Walton, S.4
  • 23
    • 68949149916 scopus 로고    scopus 로고
    • Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4, guidelines of care for the management and treatment of psoriasis with traditional systemic agents
    • Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4, guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J AmAcad Dermatol. 2009;61(3):451-485.
    • (2009) J AmAcad Dermatol. , vol.61 , Issue.3 , pp. 451-485
    • Menter, A.1    Korman, N.J.2    Elmets, C.A.3    et al.4
  • 24
    • 0038104272 scopus 로고    scopus 로고
    • Prevalence of joint disease in patients with psoriasis: Implications for therapy
    • Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol. 2003;4(7):441-447.
    • (2003) Am J Clin Dermatol. , vol.4 , Issue.7 , pp. 441-447
    • Zachariae, H.1
  • 26
    • 84888774024 scopus 로고    scopus 로고
    • Risk of moderate to advanced kidney disease in patientswith psoriasis: Population-based cohort study
    • Wan J,Wang S, Haynes K, DenburgMR, Shin DB, Gelfand JM. Risk of moderate to advanced kidney disease in patientswith psoriasis: population-based cohort study. BMJ. 2013;347:f5961.
    • (2013) BMJ , vol.347 , pp. f5961
    • Wan, J.1    Wang, S.2    Haynes, K.3    Denburg, M.R.4    Shin, D.B.5    Gelfand, J.M.6
  • 28
    • 84908234616 scopus 로고    scopus 로고
    • Accessed February 16, 2014
    • The Cochrane Collaboration. Cochrane agenda and priority settingmethods group. http://capsmg .cochrane.org/approaches-used-cochrane -review-groups-prioritization. Accessed February 16, 2014.
    • Cochrane Agenda and Priority Settingmethods Group
  • 30
    • 33845243126 scopus 로고    scopus 로고
    • Improving the use of research evidence in guideline development, 2: Priority setting
    • Oxman AD, Schünemann HJ, Fretheim A. Improving the use of research evidence in guideline development, 2: priority setting. Health Res Policy Syst. 2006;4:14.
    • (2006) Health Res Policy Syst. , vol.4 , pp. 14
    • Oxman, A.D.1    Schünemann, H.J.2    Fretheim, A.3
  • 32
    • 84908225852 scopus 로고    scopus 로고
    • Accessed November 21, 2013
    • Cochrane Skin Group.Howare titles prioritized? http://skin.cochrane.org/titles. Accessed November 21, 2013.
    • Howare Titles Prioritized?
  • 35
    • 84871036375 scopus 로고    scopus 로고
    • Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010 [supplementary appendix]
    • Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 [supplementary appendix]. Lancet. 2012;380 (9859):2095-2128.
    • (2012) Lancet , vol.380 , Issue.9859 , pp. 2095-2128
    • Lozano, R.1    Naghavi, M.2    Foreman, K.3    et al.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.